Oncternal Therapeutics Inc - Asset Resilience Ratio

Latest as of September 2024: 9.61%

Oncternal Therapeutics Inc (ONCT) has an Asset Resilience Ratio of 9.61% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$1.50 Million

Cash + Short-term Investments

Total Assets

$15.60 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2007–2023)

This chart shows how Oncternal Therapeutics Inc's Asset Resilience Ratio has changed over time. Check Oncternal Therapeutics Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Oncternal Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Oncternal Therapeutics Inc stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$1.50 Million	9.61%
Total Liquid Assets	$1.50 Million	9.61%

Asset Resilience Insights

Limited Liquidity: Oncternal Therapeutics Inc maintains only 9.61% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Oncternal Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Oncternal Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Royalty Pharma Plc NASDAQ:RPRX	Biotechnology	0.11%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Apogee Therapeutics, Inc. Common Stock NASDAQ:APGE	Biotechnology	47.01%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Beijing Hotgen Biotech Co Ltd SHG:688068	Biotechnology	20.87%

Annual Asset Resilience Ratio for Oncternal Therapeutics Inc (2007–2023)

The table below shows the annual Asset Resilience Ratio data for Oncternal Therapeutics Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	75.03%	$27.56 Million	$36.73 Million	+36.31pp
2022-12-31	38.72%	$26.58 Million	$68.65 Million	--
2021-12-31	0.00%	$0.00	$93.58 Million	--
2018-12-31	0.64%	$200.00K	$31.32 Million	-60.10pp
2017-12-31	60.74%	$28.08 Million	$46.24 Million	+7.85pp
2016-12-31	52.89%	$12.96 Million	$24.50 Million	+5.44pp
2015-12-31	47.45%	$15.20 Million	$32.03 Million	-14.57pp
2014-12-31	62.02%	$31.41 Million	$50.65 Million	+60.74pp
2013-12-31	1.28%	$200.00K	$15.61 Million	-12.64pp
2012-12-31	13.92%	$8.04 Million	$57.77 Million	+0.25pp
2011-12-31	13.68%	$10.70 Million	$78.18 Million	+12.98pp
2010-12-31	0.70%	$450.00K	$64.25 Million	-14.59pp
2009-12-31	15.29%	$8.82 Million	$57.72 Million	+13.29pp
2008-12-31	2.00%	$2.16 Million	$108.11 Million	-4.15pp
2007-12-31	6.14%	$9.81 Million	$159.73 Million	--

pp = percentage points

About Oncternal Therapeutics Inc

NASDAQ:ONCT USA Biotechnology

Market Cap

$1.56 Million

Market Cap Rank

#30219 Global

#6069 in USA

Share Price

$0.53

Change (1 day)

+0.00%

52-Week Range

$0.53 - $0.53

All Time High

$3533.60